我是妙佑医疗国际专攻多发性硬化症的神经科医生 Oliver Tobin。在本视频中,我们将介绍多发性硬化症的基础知识。什么是多发性硬化症?谁会患上多发性硬化症?它的症状、诊断和治疗情况如何?无论您是在为自己还是您关爱的人寻求答案,我们都会为您提供最佳可获信息。多发性硬化症是一种免疫系统异常攻击大脑、视神经和脊髓中的神经细胞保护膜(称为髓鞘)而引起的疾病。该保护膜通常比作电线的绝缘层。保护膜受损后就会暴露出真正的神经纤维,造成其中的神经信号传导减慢或受阻。神经纤维本身也可能受损。身体可以修复髓鞘的损伤,但不能恢复如初。由此产生的损伤会留下病变或疤痕,这就是这个名字的由来:多发性硬化症、多发性硬化疤痕。随着年龄的增长,每个人的脑细胞和脊髓神经细胞都会逐渐减少。但是,如果部分大脑或脊髓因多发性硬化症受损,该区域的神经细胞会比周围正常区域的细胞更快死亡。这种进展非常缓慢,通常持续数十年,一般表现为几年内逐渐出现行走困难。当您阅读有关多发性硬化症的信息时,会了解到不同类型的病症,其中最常见的是复发缓解型多发性硬化症。这种类型以发作或复发为特征。
虽然我们不知道导致多发性硬化症的确切原因,但已了解到某些因素可能会增加患病风险或诱发发病。虽然多发性硬化症可发生于任何年龄段,但通常见于 20 至 40 岁人群。体内维生素 D 水平低和阳光照射少(阳光可促进身体合成维生素 D)会使罹患多发性硬化症的风险增大。患有多发性硬化症且维生素 D 水平低的患者往往病情更严重。超重的人更易罹患多发性硬化症,而患有多发性硬化症且超重的人往往病情更严重、进展更快。患有多发性硬化症且吸烟的人往往复发率更高,进行性疾病和认知症状也更严重。女性患复发缓解型多发性硬化症的几率是男性的三倍。普通人群患多发性硬化症的风险约为 0.5%。如果父母或兄弟姐妹患有多发性硬化症,那您的患病风险大约是普通人的两倍,即 1%。某些感染也是重要的因素。有多种病毒与多发性硬化症有关,包括引起单核细胞增多症的 EB 病毒。多发性硬化症在纬度较高的地区更为常见,包括加拿大、美国北部、新西兰、澳大利亚东南部和欧洲。白人(尤其是北欧血统的白人)患多发性硬化症的风险最高。亚裔、非裔和美洲原住民的风险最低。如果患者有其他自身免疫性疾病,如甲状腺疾病、恶性贫血、银屑病、1 型糖尿病或炎性肠病,则罹患多发性硬化症的风险较高。
What is multiple sclerosis? National Multiple Sclerosis Society. https://www.nationalmssociety.org/What-is-MS. Accessed June 10, 2024.
Clinical overview: Multiple sclerosis. Elsevier Point of Care. 2023. https://www.clinicalkey.com. Accessed June 19, 2024.
Olek MJ, et al. Clinical presentation, course, and prognosis of multiple sclerosis in adults. https://www.uptodate.com/contents/search. Accessed June 19, 2024.
Olek MJ, et al. Pathogenesis and epidemiology of multiple sclerosis. https://www.uptodate.com/contents/search. Accessed June 19, 2024.
Olek MJ, et al. Evaluation and diagnosis of multiple sclerosis in adults. https://www.uptodate.com/contents/search. Accessed June 19, 2024.
Olek MJ, et al. Treatment of acute exacerbations of multiple sclerosis in adults. https://www.uptodate.com/contents/search. Accessed June 19, 2024.
Olek MJ, et al. Initial disease-modifying therapy for relapsing-remitting multiple sclerosis in adults. https://www.uptodate.com/contents/search. Accessed June 19, 2024.
Olek MJ, et al. Clinical use of monoclonal antibody disease-modifying therapies for multiple sclerosis. https://www.uptodate.com/contents/search. Accessed June 19, 2024.
Olek MJ, et al. Clinical use of oral disease-modifying therapies for multiple sclerosis. https://www.uptodate.com/contents/search. Accessed June 19, 2024.
Olek MJ, et al. Symptom management of multiple sclerosis in adults. https://www.uptodate.com/contents/search. Accessed June 19, 2024.
Olek MJ, et al. Overview of disease-modifying therapies for multiple sclerosis. https://www.uptodate.com/contents/search. Accessed June 19, 2024.
Olek MJ, et al. Manifestations of multiple sclerosis in adults. https://www.uptodate.com/contents/search. Accessed June 19, 2024.
Jankovic J, et al., eds. Multiple sclerosis and other inflammatory demyelinating diseases of the central nervous system. In: Bradley and Daroff's Neurology in Clinical Practice. 8th ed. Elsevier; 2022. https://www.clinicalkey.com. Accessed June 19, 2024.
Pizzorno JE, et al., eds. Multiple sclerosis. In: Textbook of Natural Medicine. 5th ed. Elsevier; 2021. https://www.clinicalkey.com. Accessed June 19, 2024.
Krämer J, et al. Bruton tyrosine kinase inhibitors for multiple sclerosis. Nature Reviews Neurology. 2023; doi:10.1038/s41582-023-00800-7.
Pediatric MS. National Multiple Sclerosis Society. https://www.nationalmssociety.org/for-professionals/for-healthcare-professionals/managing-and-treating-ms/pediatric-ms. Accessed June 19, 2024.
Multiple sclerosis. National Institute of Neurological Disorders and Stroke. https://www.ninds.nih.gov/health-information/disorders/multiple-sclerosis#. Accessed June 24, 2024.
Saadeh RS, et al. CSF kappa free light chains: Cutoff validation for diagnosing multiple sclerosis. Mayo Clinic Proceedings. 2022; doi:10.1016/j.mayocp.2021.09.014.
Nimmagadda R. Allscripts EPSi. Mayo Clinic. May 13, 2024.
Deb C. CD8+ T cells cause disability and axon loss in a mouse model of multiple sclerosis. PLOS One. 2010; doi:101371/journal.pone.0012478.
Fadul CE, et al. Safety and immune effects of blocking CD40 ligand in multiple sclerosis. Neurology Journals. 2021; doi:10.1212/NXI.0000000000001096.
Nakamura K, et al. Ibudilast reduces slowly enlarging lesions in progressive multiple sclerosis. Multiple Sclerosis Journal. 2024; doi:10.1177/13524585231224702.
Katz Sand I, et al. Mediterranean diet is linked to less objective disability in multiple sclerosis. Multiple Sclerosis Journal. 2023; doi:10.1177/13524585221127414.
Kantarci OH, et al. Novel immunomodulatory approaches for the management of multiple sclerosis. Clinical Pharmacology & Therapeutics. 2014; doi:10.1038/clpt.2013.196.